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Summary A comprehensive survey of late effects (physical, social and reproductive) following treatment at a single institution forearly stage
Hodgkin's disease (HD) was performed. A total of 611 patients with stage I and 11 HD treated between 1973 and 1984 were reviewed; 460
were alive and were mailed a self-reported questionnaire. A total of 363 (79%) replies were received. Twenty patients died of second
malignancy, 14 of heart disease and nine from respiratory disease. There were 37 cases of second malignancy [relative risk (RR) 2.2,
absolute excess risk (AR) 35.8]. The 15-year incidence of heart disease was 11% and there were nine myocardial infarction deaths (RR 1.55,
AR 5.4). Twenty-eight (8%) respondents stated that their career had been greatly interfered with, 53 (14.5%) perceived financial loss. Sexual
activity was disrupted in 25.8%. In total, 56 men had fathered 112 pregnancies. Of 171 women, 40.3% became pregnant, resulting in 92 live
births. A total of 43 men and 16 women had sought medical advice with regard to infertility.
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Advances in the diagnosis, and use of radiation therapy and
chemotherapy, have greatly improved the survival of patients
with Hodgkin's disease over the past two to three decades.
Approximately 70% of all patients can now be cured, and for
patients with early disease (stage I and II) this figure approaches
95% (Gospodarowicz et al, 1992a; Hoppe, 1990). Increasing
numbers ofpatients are surviving and are at risk for late complica-
tions oftreatment. Optimization ofprimary therapy should include
consideration of potential late toxicities in addition to the more
immediate goals of disease eradication and reduction in acute
morbidity. Although individual late effects following treatment for
all stages of HD have been documented by many centres (Hoppe,
1990; Cosset et al, 1991a; Boivin et al, 1992; Henry-Amar, 1992;
Valagussa et al, 1992; van Tulder et al 1994; Mauch et al, 1995),
this study attempts to determine comprehensively the late effects
following treatment for early stage HD at our centre.
Excellent results of treatment have been achieved using
different treatment strategies in various countries. As well as treat-
ment results, it is essential to report late complications as a means
of selecting treatments with the best chance of cure and the least
risk oftoxicity. We report our experience with late morbidity asso-
ciated with treatment of early stage HD at the Princess Margaret
Hospital (PMH).
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MATERIALS AND METHODS
Patient population and treatment details
The study population for this report comprised all patients with
stage I and II Hodgkin's disease treated at the PMH between 1973
and 1984. The total number of patients was 611 (332 men, 279
women) with a median age at diagnosis of31 years (range 17-90).
Patients were staged according to the Ann Arbor classification
based on physical examination, complete blood count (CBC),
sedimentation rate, liver function tests, chest radiograph and
bipedal lymphography, supplemented after 1980 by computerized
tomography (CT) scan of abdomen and pelvis. Only 38 (6.2%)
patients had staging laparotomy. The choice of treatment was
determined according to prognostic factors as reported previously
(Sutcliffe et al, 1985; Gospodarowicz et al, 1992a, b). The extent
of disease and treatment, including stage, histology, treatment
modality, extentofradiation and chemotherapy, is shown inTable 1.
Extended field radiation was delivered to 245 patients (41.2%) and
consisted of a mantle field followed by upper abdominal irradia-
tion to the para-aortic lymph nodes and spleen after a 4-week
interval. A total of246 patients (41.5%) received mantle radiation
or inverted Y radiation for infradiaphragmatic disease, and 103
patients (17.3%) received involved field radiation only. Mantle
fields were treated with equally weighted anterior and posterior
parallel pair technique with attenuation to compensate for contour
irregularity. A total of230 patients (37.6%) were treated with one
field a day. The usual radiation dose and fractionation schedule
was 3500 cGy given in 20 daily treatments over 28 days, delivered
by a cobalt unit with extended SSD. A total of 357 (60.1%)
patients received 3500 cGy in 20 fractions. Pneumococcal vaccine
or prophylactic antibiotics were not routinely given to patients
following upper abdominal radiotherapy (RT). A total of 193
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Table 1 Patient characteristics and treatment
n (%)
Stage IA 210 34.4
IB 13 2.1
IIA 302 49.4
IIB 86 14.1
Histology
Lymphocyte predominant 76 12.4
Nodular sclerosing 386 63.2
Mixed cellularity 119 19.5
Lymphocyte depleted 13 2.1
Unclassified 17 2.8
Treatment
XRT alone 295 48.3
CT and RT 193 31.6
CT alone 17 2.8
XRT and salvage CT 106 17.3
Extent of XRT
Involved field 103 17.3
Mantle/inverted Y 246 41.4
Extended field 245 41.2
Chemotherapy
MOPP/MOPP-like 189 90.0
ABVD/MOPP hybrid 12 5.7
ABVD 2 0.9
Other 7 3.4
(31.6%) patients had initial combined modality therapy (CMT):
external beam radiotherapy (XRT) given following three or six
courses of chemotherapy. Seventeen patients were treated with
chemotherapy alone. Most commonly (90%) MOPP or MOPP-
type, chemotherapy was used in initial treatment. A total of 149
(71%) patients had three courses of chemotherapy whereas 28
(13.3%) had six or more. An additional 106 patients (17.3%) had
chemotherapy following XRT for salvage.
Collection of late effects data
A comprehensive database, containing details ofall clinical events
from completion of primary treatment to the point of last follow-
up or death, was established. For surviving patients, additional
information on socioeconomic issues and fertility were collected.
The information was collected from the following sources: (1)
PMH medical records; (2) outside death certificates; (3) autopsy
reports when available; (4) clinical notes, pathology andradiology
reports, laboratory data from other hospitals; (5) patient question-
naire; (6) family doctor questionnaire. Surviving patients were
asked to complete an itemized self-reported questionnaire
requesting details of all illnesses since completion of therapy for
HD. The questionnaire was mainly of a structured format with
multiple choice answers and was piloted with the first 15 respon-
dents who had follow-up interviews. In addition to physical health
data including illnesses other than HD, fertility, etc., the question-
naire also collected information on activity levels, employment,
marital status and life insurance (see Appendix). Follow-up phone
calls and second mailings were made to all patients as necessary.
The information thus obtained was cross-checked with the PMH
records and any previously undocumented events disclosed by the
questionnaires were followed-up and verified. The family physi-
cians of all surviving patients were mailed a questionnaire
requesting details of any illnesses diagnosed after the completion
oftreatment forHodgkin's disease.
Statistical method
Survival curves were generated by the method of Kaplan and
Meier (Kaplan and Meier, 1958) and compared using the log-rank
test (Mantel, 1966). Cause-specific survival was calculated by
adjusting for deaths with no clinical or pathological evidence of
Hodgkin's disease at the time ofdeath. Mortality rates for second
malignant neoplasms and myocardial infarction were also calcu-
lated on an actuarial basis. The estimation ofthe probability for an
event(heart disease or second malignancy) at 15 years forCMT vs
RT, spleen irradiation or not, and mediastinum irradiated or not,
was calculated based on the Kaplan-Meier method. The expected
numberofmalignancies andthe expected numberofdeaths caused
by myocardial infarction corrected for age, gender and calendar
year was calculated by applying the incidence and mortality rates,
and the age- and sex-specific incidence and mortality in Ontario
for the period 1973-84, [20 years of cancer incidence 1964-83,
Ontario Cancer Registry, The Ontario Cancer Treatment and
Registry Foundation, and Vital Statistics for 1973, (all vols to
1984), The Province of Ontario]. The chi-square test was used to
determine the statistical significance of differences between
observed and expected incidence of malignancy and myocardial
deaths. The confidence intervals for the relative risks were calcu-
lated under the assumption that the number of primary tumours
has a Poisson distribution. The absolute excess risk per 10 000
person-years was calculated by subtracting the expected number
of cases from the observed, dividing by person-years at risk and
multiplying the result by 10 000. The proportional hazard model
was used to estimate the risks of heart disease and second malig-
nancy adjusted for age.
RESULTS
Mortality and morbidity
The median follow-up was 11 years, the range was 0.7-18 years.
Twentypatients were losttofollow-up; however, only fivepatients
had a follow-up of less than 5 years. A total of 151 deaths have
occurred and 460 (75%) patients were alive at the time ofanalysis.
Overall, 365 of the surviving patients completed the patient ques-
tionnaire (79%) and 336 (73%) of the surviving patients' family
doctors returned their questionnaires. We were able to supplement
the information from the PMH records with information from the
patient and/or the family doctor in 89% ofcases.
Ninety of the 151 deaths (60%) were either directly caused by
Hodgkin's disease or were associated with active Hodgkin's
disease at the time of death. Sixty-one deaths (40% of the total)
occurred in patients with no evidence of active Hodgkin's disease
(intercurrent deaths). Actuarial survival and cause-specific survival
at 15 years for the whole group was 70.1% and 82.3% respectively
(Figure 1). The causes of death are shown in Table 2. After
Hodgkin's disease, the major causes of mortality were second
malignant neoplasms and ischaemic heart disease and/or cardiac
failure (Table 2). The intercurrent death rate among patients treated
with XRT alone did not differ significantly from that of patients
exposed to both chemotherapy and radiation therapy (P = 0.58).
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Cause of death All XRT CMT CT
HD 90 51 29 10
Malignancy 20 15 5 0
Heart disease 11 9 2 0
Respiratory disease 5 5 0 0
CVA 4 3 1 0
Sudden 3 2 1 0
Suicide 1 1 0 0
Other 17 11 4 2
Total 151 97 42 12
Figure 1 Survival and cause-specific survival for all patients. -0-,
Overall survival; ----A---- cause-specific survival.
Second malignant neoplasms
Excluding non-melanomatous skin cancer, 37 patients developed
a second malignant neoplasm (SMN), and in 20 SMN was the
cause of death. The actuarial rate of SMNs was 9.7% (13%
including non-melanomatous skin cancer) at 15 years (Figure 2).
The acute leukaemia actuarial rate was 1.13% at 15 years, for
non-Hodgkin's lymphoma it was 1.64% and for other solid
neoplasms 6.93%. A list of first SMNs is given in Table 3. The
risks of developing SMN did not differ significantly between the
treatment groups, radiation alone, radiation and salvage
chemotherapy or CMT (P = 0.4).
The observed number of second malignancies was 37 (three
patients developed athird malignancy) compared with an expected
incidence of 16.5 in the age-matched population ofOntario for the
same time period, giving a relative risk (RR) of 2.24 (95%
confidence interval 1.57-3.08) and an absolute excess risk per
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10 000 person-years (AR) of35.8. The RR was higher in younger
patients; those under the age of 30 at the time of treatment had a
RR of 6.67 (95% CI 3.55-11.4) in contrast to a RR of 1.65 (95%
CI 1.1-2.45) for patients over the age of 30.
The observed and expected incidence of non-Hodgkin's
lymphoma, acute leukaemia, lung cancer and breast cancer along
with the relative risks and 95% confidence limits is shown inTable
4. Six women developed breast cancer and all but one were less
than 30 at the time oftreatment ofHodgkin's disease. The median
age at treatment was 25.5 (range 19-43), the median interval to the
development ofbreast cancer was 10 years. One woman who was
43 at the time of her treatment for Hodgkin's disease developed
breast cancer 3 years later. Only 38 patients had a splenectomy;
therefore, the effect of splenectomy on the risk of second malig-
nancy could notbe assessed. However, the spleen was irradiated in
275 patients with a 15-year actuarial risk of second malignancy of
10% compared with 15% in 349 patients who did not have splenic
irradiation (P = 0.1); there was no difference in length offollow-up
between the two groups. By Cox proportional hazard model
analysis for relative risk of second malignancy increasing age
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Figure 2 Actuarial rate of second malignant neoplasms. The time from diagnosis of Hodgkin's disease to the diagnosis of acute leukaemia, non-Hodgkin's
lymphoma or breast cancer is marked for each patient.
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Table 3 Second malignancy, cardiac and pulmonary disease
Incidence
Second malignancy
Lung
Lymphoma
Breast
Acute leukaemia
Colon
Oesophagus
Myeloma
Skin
Other (cervix, oral cavity, prostate, testis, vulva)
Cardiac disease
Myocardial infarction
IHD without Ml
Pericarditis
Valvular heart disease
Arrythmia
Cardiac Failure
Multiple
Other cardiac
Pulmonary disease
Asthma
COPD
Before treatment
After treatment
Pneumothorax
Pneumonitis/fibrosis
Tracheal stenosis
8
6
6
5
2
1
1
14
5
21
10
6
4
2
2
3
2
Mortality
8
4
2
4
0
1
0
0
9
0
1
0
0
0
2
0
4
4
6
3
15
1
0
0
0
4
1
IHD, ischaemic heart disease; COPD, chronic obstructive pulmonary disease.
(30 years old at time of diagnosis) was a significant factor
(RR 2.1:1, P = 0.035), but not gender, treatment modality or
splenic radiation.
Cardiac disease
A total of 50 patients, without a prior history of heart disease,
developed some form of cardiac morbidity after treatment for
Hodgkin's disease. There were 11 deaths attributed to cardiac
disease. The various forms of cardiac disease that arose are listed
in Table 3. The actuarial risk ofheart disease was 11% at 15 years,
13% for those treated by XRT alone and 7% for the CMT group.
The actuarial incidence of heart disease occurring in patients
whose mediastinum was irradiated (10% at 15 years) was
compared with those who had no mediastinal radiation (12% at
15 years, P = 0.15). The patients who had no mediastinal RT were
older at diagnosis than those who had mediastinal irradiation
(mean age 39 vs 33 years, P = 0.0001). By Cox proportional
hazard model the only factors significant for increased risk
of cardiac disease were male gender (P = 0.02) and older age
(P = 0.0001). Mediastinal radiation was not a significant factor
(P = 0.5). We were unable to obtain data for the incidence ofheart
disease for Ontario. However, age, gender and calendar year data
were available on the incidence ofmyocardial infarction mortality
for Ontario for 1973-84. The observed incidence was 9, expected
5.8 (RR 1.55, 95% confidence limits 0.71-2.95, chi-square
P = 0.18, Table 4, AR 5.4).
Respiratory disease
Table 3 outlines the incidence of respiratory disease. There were
no deaths from respiratory disease in the CMT group. In the RT
alone group there were three deaths from pneumonitis or
pulmonary fibrosis and one post-operative complication death
after surgical repair of tracheal stenosis that occurred following
emergency tracheostomy at diagnosis of Hodgkin's disease. One
patient in the CMT group developed non-fatal adult respiratory
distress syndrome after high-dose therapy with autologous bone
marrow transplantation. There was no increase in pulmonary
disease with the addition ofchemotherapy.
Herpes zoster
A total of 101 patients (16.5%) developed a herpes zoster infec-
tion, including ten patients who had more than one episode, and
six who developed generalized herpes zoster infection. There were
no fatalities. The median time to development of zoster was
1.7 years (0.1-17.1). There was a significant difference in actu-
arial zoster rate between those treated by XRT alone (15% at
15 years) and those exposed to both XRT andchemotherapy (27%
at 15 years, P = 0.001).
Thyroid disease
A total of 545 patients had radiation to their neck; abnormalities
of the thyroid gland or thyroid function were documented in 93
(17%). Three categories of thyroid disease were defined: hyper-
thyroidism in eight patients (1.5%), hypothyroidism in 77
patients (14.1%) and benign thyroid nodules in eight patients
(1.5%). For the purpose of this study hypothyroidism was
defined as patients requiring thyroid replacement therapy.
During the time period of the study there was no standard for
when thyroid replacement therapy was started. No cases of
thyroid cancer were observed.
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Table 4 Relative risk of the incidence of malignancy and of myocardial infarction mortality
Observed Expected P-value RR Cl AR
All 37 16.5 < 0.0001 2.2 1.6-3.1 34
Female 19 7.2 <0.0001 2.7 1.6-4.1
Male 18 9.4 0.004 1.9 1.1-3
Leukaemia
All 5 0.48 < 0.0001 10.4 3.4-24 7.9
Female 1 0.17 < 0.05 5.9 0.2-33
Male 4 0.31 < 0.0001 13 3.5-33
Lymphoma 6 0.21 <0.0001 29 10-62 10.1
Female 3 0.08 < 0.0001 38 8-110
Male 30 0.13 <0.0001 23 5-67
Lung
All 8 2.4 0.0003 3.33 1.5-7 9.8
Female 4 0.4 < 0.0001 9 2.5-24
Male 4 1.93 0.15 2 0.6-5
Breast
Female 6 2.1 0.006 2.9 1.1-6.3 14.7
Myocardial infarction mortality
All 9 5.8 NS 1.55 0.7-3.0 5.4
Male 8 4.0 NS 1.86 0.8-3.7
Female 1 1.5 NS 0.67 0.02-3.7
Physical activity
All but two patients responded to the question on current physical
activity. A total of325 respondents (88.8%) described their current
physical condition as normal or had minor complaints. Only four
(1.1%), required frequent assistance or were disabled and required
special care. Ten did not respond to the question on exercise or
sport activities and, of those who did, 331 (90.4%) said they had
no or little restriction on exercise, whereas 6 (1.6%) said their
activity was very restricted.
Effects on fertility
A total of 364 (79.1%) surviving patients completed question-
naries and provided the data for the following sections. In this
section, CMT refers to patients who received planned
chemotherapy and radiation or radiation followed by salvage
chemotherapy.
Female fertility
A total of 149 women completed the questionnaire items
regarding fertility. Following the treatment for Hodgkin's disease,
54 women became pregnant, resulting in 95 live births from 134
pregnancies. Thirty women became pregnant following treatment
with RT alone (out of 82 respondents), five (out of 18) after XRT
and salvage chemotherapy and 19 after CMT (out of 47). Of
women who had MOPP or MOPP-like chemotherapy, 12 (out of
31 respondents) became pregnant after three or fewer courses,
whereas five (out of 14) had four or more courses. Only one
congenital abnormality (a minor septal heart defect that closed
spontaneously) was reported. Twenty pregnancies resulted in
miscarriages and there were 19 therapeutic abortions. A total of
167 women responded to the question, 'Have you been as
successful as you wished in becoming pregnant?' Fifteen (12.8%)
of 117 who had XRT alone and nine (18.4%) of49 who had CMT
stated they had not, but overall 143 (85.6%) stated that they had.
Sixteen of 170 (9.4%) respondents stated that they had sought
medical advice for infertility.
Menstruation
A total of 148 of the 170 female respondents were premenopausal
at the time of their Hodgkin's treatment. In 21 women (ten after
XRT and 11 after CMT) periods stopped and neverrestarted; in 22
women (13 after XRT, nine after CMT) periods stopped and
restarted. The interval between stopping and restarting was 2-60
months (median 4.5 months).
Male fertility
A total of 191 men responded to the questionnaire items regarding
fertility, andofthese 57 had fathered 112pregnancies. Thirty-eight
men fathered pregnancies followed XRT (out of 100 respondents)
five following XRT and salvage chemotherapy (out of29) and 13
(out of 59) followed CMT, and one followed chemotherapy alone
(out of three). Of men who received MOPP or MOPP-like
chemotherapy ten fathered pregnancies after three or fewer
courses (out of47 respondents) and three (out of 12) who had four
or more courses. A total of 147 men indicated that they were as
successful as they wished in becoming a father. Twenty-eight
(22%) of 127 who had XRT alone, one of three who had
chemotherapy alone and 16 (28%) of57 who had CMT stated that
they had not. Forty-three of the 192 (22.5%) respondents stated
that they had sought medical advice for infertility.
Effects of treatment on socioeconomic factors
Marriage
A total of 366 patients answered the questions relating to marital
status. Of 235 who were married at the time of treatment for
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Hodgkin's disease, 177 (75.3%) remain married to the same
partner and 47 (20%) have since divorced. Nineteen (40.4%) of
these believed that the Hodgkin's disease (and its treatment) had
had an adverse effect on their marriage and eight did not comment.
Conversely, 40 (23.3%) of those who remained married believed
that having Hodgkin's disease had had a favourable effect on their
marriage. A total of 131 ofthe respondents were single at the time
of treatment and 79 have subsequently married. A total of 102
considered that the disease did not affect their marital prospects,
whereas 10 of the 47 who have remained unmarried believed that
having Hodgkin's disease had unfavourably affected their
marriage prospects.
Sexual relations
A total of 353 patients responded to questions regarding sexual
relations. Two hundred and thirty-nine patients reported no
change, 90 patients reported a temporary reduction and 23
reported a permanent reduction in their desire for sexual relations
following treatment. There was no significant difference between
those treatedby XRT, XRT followed by salvage chemotherapy and
those who received CMT (P = 0.087).
Finances and insurance
A total of 362 patients answered a question regarding the long-
term effects on finances and ofthese 53 (14.6%) reported that they
were worse off financially as a result of their disease. A total of
174 patients had applied for life insurance following HD and 125
(71.8%) had experienced difficulty. Sixty-nine of those experi-
encing difficulty were eventually successful, but 29 believed that
theirpremium had been excessively 'loaded'.
Employment
A total of 192 men and 172 women responded to the questions
concerning employment. Three men and one woman were unem-
ployed at diagnosis of Hodgkin's disease and at the time of the
questionnaire the corresponding figures were 12 men and 11
women. However, the total number ofemployed and homemakers
before treatment was 293 and at the time of the study it was 300.
The numberofstudents fell from 60 to 5 and the number ofretired
rose from 7 to 32. Twenty-eight patients (7.8%) considered that
their career had been greatly affected whereas 84 (23.5%) thought
that it had been slightly affected by their illness.
DISCUSSION
There have been many reports on late effects of treatment for
Hodgkin's disease, mostly reporting on patients with all stages of
disease. This study reports the results of an extensive review of
late effects of treatment of a consecutive group of patients with
stage I and II HD treated at a single institution. We address toxici-
ties, including second malignancy and other illnesses, and also
other effects such as exercise tolerance, psychological and sexual
problems.
The increased risk of second malignancy after treatment of
Hodgkin's disease has been recognized for more than two decades.
The largest analysis of second malignancy was conducted by the
InternationalDataBase on Hodgkin's Disease (IDHD) (Henry-Amar,
1992) which includes the patients in the current study. There have
been many others describing the relative risk of second malignancy
as ranging from 1.86 to 6.8 and the 15-year incidences of second
malignancy ranging from 11.2% to 18% (Hancock et al, 1988;
Tucker et al, 1988; Cosset et al, 1991a; Henry-Amar, 1992;
Swerdlow et al, 1992; Abrahamsen et al, 1993; Dietrich et al, 1994;
van Leeuwen et al, 1994; Mauch et al, 1995; Bhatia et al, 1996). All
studies showed a significant increased risk of second malignancies,
in particular for acute leukaemia, non-Hodgkin's lymphoma and
solid tumours. The relative risks of non-Hodgkin's lymphoma and
leukaemia are considerably higher than for solid cancers because of a
relative rarity of non-Hodgkin's lymphoma (NHL) and leukaemia
compared with solid cancers. The Late Effects Study Groups (Bhatia
et al, 1996) differs from the other studies as all patients entered were
under the age of 16 at the time of treatment for Hodgkin's disease.
Several reports (Hancock et al, 1988; Rodriquez et al, 1993; Biti
et al, 1994; Dietrich et al, 1994; van Leeuwen et al, 1994) indi-
cated that age greater than 40 at the time of diagnosis was associ-
ated with an increased risk of second maligancies. Although the
AR increased with age, because malignancy is more common with
increasing age, the relative risk of developing a second malig-
nancy was greater in younger patients in this study, as has been
reported by others (Henry-Amar, 1992; Swerdlow et al, 1992).
Splenectomy has been reported as a risk factor for second malig-
nancy in some studies (van Leeuwen et al, 1994) but not others
(Valagussa et al, 1986; Swerdlow et al, 1993). The IDHD reported
a relative risk of 1.3 for development of acute leukaemia
(P < 0.05) and 1.4 for non-Hodgkin's lymphoma (P < 0.1).
Dietrich et al (1994), found that splenic irradiation as well as
splenectomy was associated with an increased risk ofdevelopment
of second malignancy. We did not find a similar effect.
An increased risk of myocardial infarction has been reported
following mediastinal radiation (Cosset et al, 1991a,b). Boivin et
al (1992) reported an increased risk ofmycoardial death at 5 years
after radiation that persisted for 10 years or more, but was seen
only in an early cohort of patients and not observed in the later
cohort, treated by more modem radiotherapy techniques. Mauch et
al (1995) reported a significantly increased cardiac mortality (RR
2.2, 1.2-3.6). In the current study there was an increased risk of
death from myocardial infarction but it was not statistically signi-
ficant (RR 1.5, CI 0.7-3.0). It is possible that the absence of an
increased RR of death from myocardial infarction relates to the
lower RT dose to the mediastinum and smaller RT fraction size
(35 Gy in 1.75-Gy fractions) than is describedby mostofthe other
series. However, in the series reported from Stanford (Hancock et
al, 1993), a persistent increased risk of myocardial infarction
mortality was observed even after subcarinal blocking was intro-
duced. The limited patient numbers and the relatively short length
offollow-up in the current study may also contribute to the failure
to find an increased risk ofdeath from myocardial infarction.
Long-term pulmonary toxicity was difficult to assess by the
questionnaire. It was difficult to exclude pre-existing pulmonary
disease and difficult to differentiate between pneumonitis and
pulmonary fibrosis. Accordingly, these were grouped together.
Eightpatients who were treated by radiation alone developedpneu-
monitis or pulmonary fibrosis and in three of these patients it was
fatal; one patient had mediastinal reirradiation and another patient,
who also developed radiation hepatitis, received standard mantle
radiation to a dose of 35 Gy in 20 fractions and upper abdominal
radiation with alternate fields per day. In comparison with the
3.75% incidence of pneumonitis in the current study, Tarbell et al
(1990) reported a 6% incidence of pneumonitis in patients treated
for stage 1A-3B Hodgkin's disease; the incidence was higher with
patients treated with combined modality therapy, whole-lung irra-
diation and also in patients with large mediastinal adenopathy.
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Herpes zoster infection may develop within 2 years oftreatment
for Hodgkin's disease in 15-20% of patients (Hoppe, 1990). In a
multi-institutional study of 717 patients with Hodgkin's disease
(Guinee et al, 1985), the incidence was related to treatment inten-
sity (11% for radiation alone and 27.5% for CMT) reflecting the
findings ofthis study, in which the 15-year actuarial incidence was
lower for radiation alone than for CMT. The study by Guinee et
al(1983) found no influence on the attack rate of infections for
stage, histology or splenectomy.
Many of the reports on thyroid function define hypothyroidism
biochemically so that any patient with a raised thyroid-stimulating
hormone (TSH) above the normal range is considered to have
hypothyroidism. The rate ofhypothyroidism in the current study is
lowerthan thatreported by other(Tarbell etal, 1990; Hancock etal,
1991; Peerboom et al, 1992) and could be due to the short follow-
up or lower dose of radiation to the neck, or related to the
differences in definitions of hypothyroidism. The Stanford series
(Hancock et al, 1991) reported a higher risk ofhypothyroidism in
patients treated at a young age, which increased with length of
follow-up and dose of radiation given. In the current study there
were eight cases ofGraves' disease, a high number, given the size
of the study. Hancock et al (1991) reported an increased risk of
Graves' disease of 7.2-20.4. Unlike Stanford, or the IDHD data,
there were no thyroid cancers observed in our cohort.
That partners ofmale patients following treatment for Hodgkins
have a lower frequency ofpregnancy than female patients and that
more men felt that they had been less successful in fathering preg-
nancies than they had wished and sought more medical advice
with regards to fertility is in keeping with other reports (Aisner et
al, 1993). Chapman et al (1981) and others (e.g. Viviani et al,
1991) reported that sperm counts may be reduced before treat-
ment. It is therefore uncertain whether the reduction in fertility is
related to the disease ratherthan the treatment. In the current study
however, the reduction in numbers of wanted pregnancies tended
to be higher in those treated with combined modality treatment
than radiation alone, suggesting that the treatment was a relevant
factor. Whether this effect will be observed in those receiving
ABVD rather than MOPP remains to be seen.
Despite differences in allocation of modalities of treatment,
stages of disease and types of questions posed, several reports
including this study have demonstrated restriction in physical
functioning, lower perceived overall health, less satisfaction with
sexual life, marital difficulties, difficulty in obtaining financial
loans and life insurance, and more health-related unemployment
limitations in patients treated for Hodgkin's disease (Fobair
et al, 1986; Komblith et al, 1992a, b; Valagussa et al, 1992; van
Tulder et al, 1994).
This study, in keeping with others, has documented an increase
risk in second maliganancy following treatment for Hodgkin's
disease. We did not show a significantly increased risk ofcardiac
disease. This may be related to the lower RT dose compared with
most series, or to the small patient numbers and the short follow-
up of this study. Change in chemotherapy practice, e.g. the
increased use ofABVD, could affect the incidence ofboth cardiac
and pulmonary disease with more prolonged follow-up. Changing
combination chemotherapy regimens may, however, be associated
with areduction in the incidence ofsecond malignancies, certainly
reduced incidence ofleukaemia and possibly reduced frequency of
problems with fertility. In the meantime, care should continue to
be given to optimize practice by the use ofgood radiotherapy tech-
niques such as two fractions a day and keeping the total dose and
fraction size to as small a dose as possible. This study has also
demonstrated the psychological, social, financial and sexual prob-
lems thatoccurinpatients following treatment forearly Hodgkin's
disease. Itis difficult toknow how much is relatedto treatment and
how much is related to the disease itself. However, it seems
unlikely that current changes in treatment management will have a
profound impact on these deleterious effects. This study demon-
strated the importance of careful follow-up after treatment for
Hodgkin's disease. Consideration should be given to screening for
the more common problems and counselling when necessary.
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APPENDIX I
Questionnaire forfemale patients
Have you developed any ofthe following illnesses or conditions since you were treated forHodgkin's disease?
Myocardial infarction [ ] No [ ] Yes
(heart attack)
Other heart disease [ ]No[ ]Yes
Thyroid disease [ ] No [ ] Yes
Kidney disease [ ] No [ ] Yes
High blood pressure [ ] No [ ] Yes
Peptic ulcer [ ] No [ ] Yes [ ] Stomach
[ ] Duodenal
[ ]Don't know
Cancer, tumour, growth or leukaemia [ ] No [ ] Yes
Lung disease [ ] No [ ] Yes
Shingles\Herpes zoster infection [ ] No [ ] Yes number ofepisodes
Liver disease [ ] No [ ] Yes
Blood disorder [ ] No [ ] Yes
Other medical problems [ ] No [ ] Yes Please specify
Have you had any surgery since you were treated for
Hodgkin's disease? [ ] No [ ] Yes Please specify
Please choose the best description ofyour current physical condition.
normal, no complaints
able to carry on normal activities with only minor complaints
can manage normal activities but only with some effort
able to care for most ofyour own needs but require occasional assistance
require considerable assistance and frequent medical care
disabled and requiring special care and assistance
Do you think your HD or its treatment has resulted in any restriction in the amount of exercise you can take or your performance in
sporting activities?
not at all restricted
[ a little restricted
quite a lot restricted
very restricted
Before you were treated for Hodgkin's disease, were you:
[ a student
employed
managing household
[ unemployed
retired
[ other. Please specify:
At present are you:
] a student
] employed
[ ] managing household
[ unemployed
[ retired
other. Please specify:
Does your current health currently keep you from working at ajob? [ ] No [ ]Yes
Does your current health currently keep you from doing householdjobs? [ ] No [ ] Yes
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How much has the Hodgkin's disease (and its treatment) interfered with progress in your career?
[ not interfered at all
[ interfered slightly
[ interfered greatly
Have you applied for life-insurance since you were found to have Hodgkin's disease?
[ No [ ] Yes did you experience any difficulty because ofyourHodgkin's disease?
[ No [ ] Yes were you eventually successful?
[ No [ I Yes has your premium been loadedbecause ofyourHodgkin's disease? [ ] No [ ] Yes
Do you think that you are currently worse-offfinancially as a result ofhaving had
Hodgkin's disease? [ ] No [ ] Yes
When you were found to have Hodgkin's disease, were you:
(A) Married (or living as married)
[ No Please go to (B) below
[ Yes 1. Have you:
[ Remained with the same partner
[ Divorced/separated and since remained single
[ Divorced/separated but now remarried (or living as married)
Other. Please specify:
2. Do you think that having Hodgkin's disease has affected your marriage?
[ favourable
[ unfavourably
]not at all
(B) Unmarried (or living as married)
]Yes 1. Have you:
] Remained single
] Married (or living as married)
] Married (orliving as married) temporarily, but now single again
] Other. Please specify:
2. Do you think that having Hodgkin's disease has affected your marriage prospects?
] favorably
] unfavorably
[ ]not at all
*What effect did the treatment for Hodgkin's disease have on yourperiods?
No periods at time ofdiagnosis and none since
Periods have continued
Periods stopped for a time, later restarted
How long did they stop for? months
[ Periods stopped and neverrestarted
[ Periods continued for a while but later stopped
How old were you when they stopped?.--years
[ Other. Please specify:
Have you been through the menopause yet?
[ ] No [ ] Yes Please state approximately how old you were when this tookplace_years
How many children did you have at the time your Hodgkin's disease was diagnosed?
Please complete results ofany pregnancies you have had since your Hodgkin's disease was diagnosed:
a) Number oflive babies
b) Number ofstillborn babies
c) Number ofmiscarriages
d) Number oftherapeutic abortions
e) Other. Please specify:
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Since your treatment for Hodgkin's disease, have you sought medical advice regarding possible infertility?
[ I No [ I Yes Please specify
Have you had any children born with congenital abnormalities (birth defects)?
[ ] No [ ] Yes Please specify
Have any ofyour children developed any serious illnesses or conditions?
[ ] No [ ] Yes Please specify
Since your treatment for Hodgkin's disease, have you been successful in becoming pregnant as you wished?
[ ] No [ ] Yes Please specify
Did the Hodgkin's disease and its treatment cause any reduction in your interest in (desire for) sexual relations?
] no reduction
[ temporary reduction
] permanent reduction
How else has Hodgkin's disease and its treatment changed/interfered with your life? Please describe below:
*QUESTIONS ASKED OF MALE PATIENTS FROM THIS POINT
How many children did you have at the time you Hodgkin's disease was diagnosed?
How many pregnancies have you fathered since your Hodgkin's disease was diagnosed (including pregnancies which ended with
miscarriages or abortions besides those which went to full term)?
Since your treatment for Hodgkin's disease, have you sought medical advice regarding possible infertility?
[ ] No [ ] Yes Please specify
Have you had any children born with congenital abnormalities (birth defects)?
[ ] No [ ] Yes Please specify
Have any ofyour children developed any serious illnesses or conditions?
[ ] No [ ] Yes Please specify
Since your treatment for Hodgkin's disease, have you been as successful in fathering pregnancies as you wished?
[ ] No [ ] Yes Please specify
Did the Hodgkin's disease and its treatment cause any reduction in your interest in (desire for) sexual relations?
[ No reduction
temporary reduction
permanent reduction
How else has Hodgkin's disease and its treatment changed/interfered with your life? Please describe below:
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